Gene therapy for liver disorder at UConn Health
The world’s first gene therapy clinical trial for glygogen stoprage disease is underway at the Connecticut Children’s Medical Center and UConn Health, under the direction...
Home >
Access the latest news, business developments, company updates, industry trends, events and more.
The world’s first gene therapy clinical trial for glygogen stoprage disease is underway at the Connecticut Children’s Medical Center and UConn Health, under the direction...
The world’s first gene therapy clinical trial for glygogen stoprage disease is underway at the Connecticut Children’s Medical Center and UConn Health, under the direction of...
Have you visited the BioCT Careers page recently? This enhanced, interactive site matches job seekers and employers in the bioscience industry throughout Connecticut. Job seekers...
Connecticut Innovations reports that it has closed on the initial $665,000 tranche of a $1 million investment in Invixium Access, a manufacturer of modern biometric solutions. Invixium was a winner...
SpringWorks Therapeutics reports that the first patient has been dosed in the Phase 3 “DeFi” (Desmoid/Fibromatosis) trial evaluating nirogacestat, an oral, selective, small molecule gamma-secretase...
Azitra has announced the appointment of two distinguished scientists to expand the technical team and lead the expansion of its development programs. Travis Whitfill, co-founder, will...
Bioarray Genetics has been selected to present at the 2019 International Cancer Cluster Showcase as part of its North American and European cutting-edge oncology innovations group....
Achillion Pharmaceuticals has reported positive interim data from a Phase 2 paroxysmal nocturnal hemoglobinuria (PNH) trial assessing the safety and effectiveness of its oral small...
IsoPlexis has raised $25 million in Series C funding. The round was led by Northpond Ventures and included new strategic investment along with current investors...
While cases of syphilis in Europe were first recorded over 500 years ago, no vaccine candidates have ever advanced to human clinical trials. A new...